7-OH vs. fentanyl: how they compare
7-OH and fentanyl are both opioids. They activate the same receptors, cause the same type of dependence and withdrawal, produce the same kind of overdose, and are treated with the same medication. Fentanyl is more potent. That is true — and it is not the most important thing about this comparison.
The most important thing is this: concentrated 7-OH has been linked to fatal overdoses in otherwise healthy young adults. Public health officials in Los Angeles County documented six overdose deaths associated with 7-OH ingestion between April and October 2025. The decedents were between 18 and 40 years old. That is not a safer drug. It is an unregulated opioid that people were buying at gas stations.
At a glance: 7-OH vs. fentanyl
Key Takeaways
- Both are opioids acting on the same mu-opioid receptors. The differences are potency, origin, and how people encounter them — not pharmacological category.
- Fentanyl is more potent. That does not make 7-OH safe. Concentrated 7-OH has been linked to fatal overdoses in otherwise healthy people. Los Angeles County public health officials documented six deaths between April and October 2025.
- There is an adulteration risk worth knowing. Unregulated products have no quality control. The FDA has reported kratom products adulterated with substances including fentanyl. This is a documented risk of an unregulated market, not a routine finding — but it is a risk a consumer cannot rule out.
- The treatment is the same. Naloxone can reverse an overdose from either. Buprenorphine treats dependence on both. The comparison that matters is not potency — it is whether there is an effective way out, and there is.
What they have in common
Start here, because this is what the comparison actually turns on.
Same receptor target. Both 7-OH and fentanyl bind and activate mu-opioid receptors. Mu-opioid receptor activation produces euphoria, sedation, pain relief, and — at sufficient exposure — respiratory depression. The mechanism of harm is the same for both.
Same trajectory. Both cause tolerance and physical dependence with regular use. Stopping produces opioid withdrawal. The symptoms, the timeline, and the clinical management are the same.
Same emergency response. Naloxone reverses opioid-induced respiratory depression from either substance. Because 7-OH has a longer effective half-life than some opioids, and because fentanyl is extremely potent, repeat doses of naloxone may be needed for either. Call 911 before or immediately after giving naloxone — naloxone wears off and the opioid may outlast it.
Same treatment. Buprenorphine (Suboxone) is the evidence-based medication for dependence on mu-opioid agonists. It works for 7-OH dependence and for opioid use disorder from fentanyl and other opioids. The pharmacological basis is the same in both cases. See how Suboxone works for kratom and 7-OH.
Where they differ
Potency
Fentanyl is substantially more potent than 7-OH at mu-opioid receptors. This article does not publish dose equivalence or conversion ratios — those figures can function as dosing guidance, which is not appropriate for either substance in an unregulated context.
State this plainly and move on: fentanyl's extreme potency is what makes it the dominant driver of opioid overdose deaths in the United States. It takes very little to cause fatal respiratory depression. 7-OH, while potent, is less potent than fentanyl.
Now the contextualization that must follow immediately: less potent than fentanyl is not a safety standard. It is true of nearly every opioid ever made. Morphine is less potent than fentanyl. Oxycodone is less potent than fentanyl. Those substances have caused hundreds of thousands of deaths. Whether something is safer than the most potent opioid in the overdose crisis has never been the relevant measure of whether it is safe to take daily.
Origin and how people encounter it
Fentanyl has two contexts: as a pharmaceutical (used for cancer pain, anesthesia, and other serious medical indications, precisely dosed under medical supervision) and as an illicit drug (manufactured in clandestine labs, potency highly variable, frequently added to other drugs as adulterant).
7-OH exists in one context: as an unregulated commercial product, sold openly as a supplement, with no standardized dosing, no manufacturing quality control, and no medical oversight.
The exposure difference cuts against 7-OH in an important way: people encountering fentanyl in the illicit supply generally know they are dealing with an opioid. People buying 7-OH at a gas station often believe they are buying a natural supplement. That gap in awareness is its own hazard — physical dependence forms before anyone recognizes what is happening. For the full picture of how that awareness gap works, see The Hidden Habit: Why 7-OH Addiction Is Easier to Hide.
Dosing precision
Pharmaceutical fentanyl is manufactured under FDA regulations to deliver precisely what the label says. Illicit fentanyl has variable and unpredictable potency.
Commercial 7-OH products are unregulated and have variable actual potency regardless of what the label says. A peer-reviewed 2025 analysis in the Journal of Analytical Toxicology found commercial products significantly exceeding their labeled 7-OH content. Two tablets from the same bottle may have different amounts of 7-OH.
Does 7-OH contain fentanyl?
7-OH and fentanyl are distinct chemical compounds. 7-OH is not fentanyl, and standard 7-OH products are not made from fentanyl.
However: unregulated products carry contamination and adulteration risk that regulated pharmaceutical products do not. The FDA has reported kratom products adulterated with substances including undeclared pharmaceutical drugs — and in CDC analyses of overdose deaths where kratom was detected, fentanyl and its analogues were the most common co-detected substances.
The honest read on that CDC data: it reflects polysubstance use patterns and contamination risks in the unregulated supply, not that commercial 7-OH products routinely contain fentanyl. Most kratom-detected overdose deaths involve multiple substances; the presence of fentanyl in the toxicology more often reflects the broader drug supply than adulteration of a specific kratom product.
What a consumer cannot do is rule out contamination. Commercial 7-OH products have no quality control requirement. When you buy an unregulated product with no manufacturing standards, you do not know what is in it.
The overdose data for 7-OH specifically
Los Angeles County Department of Public Health documented this in two alerts:
September 12, 2025 (initial alert): Three fatal overdoses among LA County residents aged 18 to 40. Alcohol was present in all three cases. No other substances were identified as substantively contributing to the deaths.
October 10, 2025 (updated alert): Three additional deaths, bringing the total to six. The update noted that alcohol was present in many of the fatal overdose cases, along with "other medications and, at times, illicit substances" — a broader characterization than the initial report.
The California Department of Public Health confirmed the six-death total and described the decedents as people "between the ages of 18 and 40."
The pattern: alcohol combined with 7-OH is where deaths concentrated in the LA County cases. High doses of 7-OH and co-use with alcohol or other sedatives produce synergistic respiratory depression. This is not a theoretical risk. It has produced documented fatalities in otherwise healthy young adults. See Dangerous Kratom Drug Interactions for the mechanism.
"At least it's not fentanyl" — why that reasoning fails
Many people use fentanyl as their benchmark for a "real drug problem." Anything that falls short of fentanyl's potency can feel manageable by comparison. That reasoning is worth examining directly.
The comparison people are making is: 7-OH is less potent than fentanyl, therefore less dangerous. The conclusion that follows from this is: I don't have a real opioid problem.
What the data shows: six deaths in LA County, alcohol present, decedents otherwise healthy and young. The CDC's analysis of kratom-detected overdose deaths across the country found that a majority involved multiple substances, with fentanyl most common — but the category also includes cases with fewer co-substances. The Blue Ridge Poison Center at UVA Health documented a case of a patient requiring inpatient medically managed withdrawal after stopping daily concentrated 7-OH use.
7-OH lacks the partial agonist ceiling that limits kratom leaf's respiratory depression risk. At the concentrations in commercial products, its effect on breathing climbs with the amount taken, and there is no natural brake. "Safer than fentanyl" is a comparison that is true of nearly every substance ever made. It has never been a standard for safety.
If you're comparing them because you're worried
Most people searching this question are not doing pharmacology research. They are trying to figure out how much trouble they are in.
The pharmacology does not settle that question, but the treatment picture does. If you are dependent on 7-OH, the treatment is the same one used for fentanyl and prescription opioid dependence. Buprenorphine stabilizes the same receptors. The case series data show it works. The comparison that matters is not how potent 7-OH is relative to fentanyl — it is that both have an established, effective treatment pathway and that treatment is available through telehealth in most states, often the same day.
If you have been telling yourself it is not a real drug problem because it is not fentanyl, this is worth a second look. See "I Only Use Kratom" — Why That Still Qualifies for MAT.
Frequently Asked Questions
Is 7-OH as strong as fentanyl?
No. Fentanyl is substantially more potent than 7-OH at mu-opioid receptors. The FDA's 2025 assessment documented 7-OH producing respiratory depression at more than three times morphine's potency; pharmaceutical fentanyl is conventionally estimated at 50 to 100 times morphine's potency. This comparison does not make 7-OH safe. It makes 7-OH a potent opioid that has caused documented fatalities, particularly when combined with alcohol.
Does 7-OH contain fentanyl?
7-OH and fentanyl are chemically distinct compounds. 7-OH products are not made from fentanyl. However, unregulated products carry adulteration risk: the FDA has documented kratom products containing undeclared pharmaceutical drugs, and in CDC analyses of kratom-detected overdose deaths, fentanyl was the most common co-detected substance. A consumer purchasing an unregulated 7-OH product cannot rule out contamination with any particular substance.
Is 7-OH safer than fentanyl?
7-OH is less potent than fentanyl. Less potent does not mean safe. Concentrated 7-OH has been linked to fatal overdoses in people aged 18 to 40 in Los Angeles County, particularly in combination with alcohol. Unregulated commercial products have inconsistent potency, no quality control, and no clinical oversight. The relevant safety question is not how 7-OH compares to the most dangerous opioid in the current drug supply — it is whether 7-OH is safe to take daily. Based on the available data, it is not.
Can naloxone reverse a 7-OH overdose?
Yes. LA County public health officials and the UVA Blue Ridge Poison Center both confirmed that naloxone can reverse 7-OH-induced respiratory depression. Repeat doses may be required because 7-OH has a longer effective half-life than some opioids, and because commercial product potency varies. Always call 911 in any suspected overdose regardless of naloxone availability or response.
Sources
- Los Angeles County Department of Public Health. Health Alert: Fatal Overdoses Associated with 7-Hydroxymitragynine (7-OH) in Los Angeles County. September 12, 2025. http://publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=5139
- Los Angeles County Department of Public Health. Additional Fatal Overdoses Tied to Synthetic Kratom in Los Angeles County. October 10, 2025. https://lacounty.gov/2025/10/10/additional-fatal-overdoses-tied-to-synthetic-kratom-in-los-angeles-county/
- California Department of Public Health. CDPH Statement on Kratom and 7-OH. 2025. https://www.cdph.ca.gov/Programs/OPA/Pages/NR25-016.aspx
- U.S. Food and Drug Administration. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. FDA; July 2025. https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf
- Olsen EO, O'Donnell J, Mattson CL, Schier JG, Wilson N. Notes from the field: unintentional drug overdose deaths with kratom detected — 27 states, July 2016–December 2017. MMWR Morb Mortal Wkly Rep. 2019;68(14):326-327. doi:10.15585/mmwr.mm6814a2.
- Drug Enforcement Administration. Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Federal Register. Published July 6, 2026. Document No. 2026-13580. https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified
- Brown J, et al. Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom. Journal of Analytical Toxicology. 2025. PMID: 41065466. https://pubmed.ncbi.nlm.nih.gov/41065466/
- Blue Ridge Poison Center, UVA Health. 7-Hydroxymitragynine Clinical Toxicology Note. August 2025. https://med.virginia.edu/toxicology/wp-content/uploads/sites/268/2025/08/Aug25-7-hydroxymitragynine.pdf